Contrasting EU and US drug development

Throughout the years of doing business on both slides of the Atlantic, a key observation has continued to influence the way we support clients with hands-on implementation focused advisory services. The US biopharmaceutical market is inundated with billions of capital for development of drugs, devices, and novel approaches, in turn attracted by a highly lucrative […]